Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.20494 billion
  • Outstanding Shares: 41,521,000
Average Prices:
  • 50 Day Moving Avg: $29.19
  • 200 Day Moving Avg: $31.04
  • 52 Week Range: $25.63 - $38.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.64
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $23.65 million
  • Price / Sales: 50.49
  • Book Value: $9.76 per share
  • Price / Book: 2.95
  • EBIDTA: ($91,810,000.00)
  • Return on Equity: -30.71%
  • Return on Assets: -26.01%
  • Current Ratio: 20.33%
  • Quick Ratio: 20.33%
  • Average Volume: 525,227 shs.
  • Beta: 0.84
  • Short Ratio: 10.06
Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira, Inc. (NASDAQ:DERM) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.72) EPS for the quarter, hitting analysts' consensus estimates of ($0.72). The company earned $0.12 million during the quarter. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

9 equities research analysts have issued 1 year price targets for Dermira's shares. Their forecasts range from $40.00 to $48.00. On average, they expect Dermira's stock price to reach $43.80 in the next twelve months. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/10/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
  • William D. Young, Chairman of the Board
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
  • Luis C. Pena, Co-Founder, Chief Development Officer
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
  • Lori Lyons-Williams, Chief Commercial Officer
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
  • Frederick B. Craves Ph.D., Lead Director, Independent Director
  • Emmanuel Caeymaex, Director
  • David E. Cohen M.D., Independent Director

Who owns Dermira stock?

Dermira's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (8.45%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $28.76.

MarketBeat Community Rating for Dermira (NASDAQ DERM)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $43.80 (52.29% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Needham & Company LLCReiterated RatingBuy$46.00LowView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
6/22/2017Cantor FitzgeraldInitiated CoverageOverweight$45.00MediumView Rating Details
5/25/2017MizuhoLower Price TargetBuy -> Buy$42.00 -> $40.00LowView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup Inc.Initiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.00)($1.00)($1.00)
Q4 20171($1.23)($1.23)($1.23)
(Data provided by Zacks Investment Research)


Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 84.59%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline logoUCB and Dermira Announce U.S. and EU Regulatory... - July 25 at 5:49 PM logoUCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis - July 25 at 3:34 AM logoETFs with exposure to Dermira, Inc. : July 24, 2017 - July 24 at 5:32 PM logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017 - July 21 at 7:35 PM logoDermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC - July 18 at 1:18 PM logoDermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts - July 17 at 12:33 PM logoETFs with exposure to Dermira, Inc. : July 14, 2017 - July 14 at 3:45 PM logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017 - July 12 at 6:28 PM logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017 - July 11 at 6:58 PM logoDermira, Inc. (DERM) Insider Sells $75,000.00 in Stock - July 6 at 8:06 PM logoInsider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock - July 5 at 7:45 PM logoDermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub - July 3 at 3:22 PM logoEvercore ISI Begins Coverage on Dermira, Inc. (DERM) - June 29 at 6:42 PM logoDermira (DERM) Reports Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition - June 26 at 10:37 PM logoBRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published - June 26 at 10:37 PM logoNewly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition - June 26 at 5:34 PM logoAnalysts Offer Predictions for Dermira, Inc.'s FY2017 Earnings (DERM) - June 26 at 7:41 AM logoDermira, Inc. (DERM) Now Covered by Cantor Fitzgerald - June 22 at 2:58 PM logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : June 22, 2017 - June 22 at 10:24 AM logoEugene A. Bauer Sells 2,500 Shares of Dermira, Inc. (DERM) Stock - June 21 at 8:04 PM logoDermira, Inc. (DERM) Given Consensus Rating of "Hold" by Brokerages - June 20 at 10:30 AM logoDermira, Inc. (DERM) Raised to Hold at BidaskClub - June 15 at 6:58 PM logoThomas G. Wiggans Sells 5,000 Shares of Dermira Inc (DERM) Stock - June 5 at 10:19 PM logoDermira to Present at Jefferies 2017 Global Healthcare Conference - May 30 at 4:38 PM logoShort Interest in Dermira Inc (DERM) Grows By 66.8% - May 28 at 7:02 AM logoDermira Inc (DERM) PT Lowered to $40.00 - May 27 at 12:58 AM logoDermira Inc (DERM) Given Average Rating of "Hold" by Brokerages - May 26 at 10:50 AM logoTeva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts - May 25 at 6:30 PM logoDermira Inc (DERM) Short Interest Up 2.9% in April - May 22 at 9:16 PM logoDERMIRA, INC. (DERM) - May 16 at 9:43 PM logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock - May 16 at 8:44 PM logoDermira Announces Closing of 3.00% Convertible Senior Notes Offering - May 16 at 4:42 PM logoDermira Inc (DERM) Expected to Earn Q2 2017 Earnings of ($0.81) Per Share - May 11 at 8:52 AM logoDermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes - May 10 at 9:51 PM logoHere's Why Dermira Fell as Much as 18.7% This Morning - May 10 at 4:51 PM logoFY2020 EPS Estimates for Dermira Inc (DERM) Cut by Analyst - May 10 at 3:38 PM logoDermira Announces Proposed Offering of $250 Million of Convertible Senior Notes - May 9 at 4:41 PM logoBRIEF-Dermira qtrly net loss per share, basic, diluted $ 0.79 - May 9 at 5:43 AM logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 9 at 5:43 AM logoDermira reports 1Q loss - May 8 at 5:36 PM logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 8 at 4:30 PM logoDermira (DERM) Earning Somewhat Favorable Media Coverage, Study Finds - May 1 at 5:44 PM logoDermira Inc (DERM) Given Consensus Rating of "Hold" by Analysts - May 1 at 2:24 PM logoDermira Inc (DERM) Expected to Announce Earnings of -$0.86 Per Share - May 1 at 10:04 AM logoDermira (DERM) Earning Somewhat Negative News Coverage, Report Finds - April 28 at 10:26 AM logoDermira (DERM) Given Coverage Optimism Score of 0.12 - April 25 at 7:30 PM logoDermira (DERM) Getting Favorable News Coverage, AlphaOne Reports - April 22 at 2:49 PM logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017 - April 20 at 4:49 PM logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017 - April 19 at 12:31 PM logoDermira (DERM) Getting Positive News Coverage, Study Shows - April 19 at 10:04 AM



Dermira (DERM) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff